<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940628-2-00059</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Written comments on the labeling may be submitted at any time.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 86D&hyph;0334]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Estrogen Drug Product Labeling; Labeling Guidance Texts; Availability</DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is announcing the availability of informal labeling guidance texts for professional and patient labeling for estrogen drug products that were last revised in 1992. The texts provide information to assist manufacturers and other persons in preparing supplemental applications to meet labeling requirements. The revisions reflect updated scientific information.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Written comments on the labeling may be submitted at any time.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Submit written requests for a copy of the labeling guidance texts to Philip A. Corfman, Division of Metabolism and Endocrine Drug Products (HFD&hyph;510), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;3510. Send two self-addressed adhesive labels to assist that office in processing your requests. Submit written comments on the labeling guidance texts to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857. Requests and comments should be identified with the docket number found in brackets in the heading of this document. The labeling guidance texts and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Deborah A. Wolf, Center for Drug Evaluation and Research (HFD&hyph;362), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1046. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> FDA is announcing the availability of the 1992 revised informal labeling guidance texts for professional and patient labeling for estrogen drug products. The 1992 revisions reflect updated scientific information, particularly pertaining to the relationship between estrogen replacement therapy and reduction of cardiovascular risk. Although, the agency has distributed copies of the 1992 labeling guidance on a case-by-case basis, it is announcing its availability now to ensure more widespread distribution. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Under 21 CFR 314.70(c), a holder of an approved application for a new drug is required to submit a supplemental application to obtain approval for the following changes, among others, in the text of professional or patient labeling: to add or strengthen contraindications, warnings, precautions, or adverse reactions, or to add or strengthen dosage and administration instructions to increase the safe use of the product. Manufacturers and other persons can refer to the labeling guidance texts for assistance in preparing supplemental applications to meet the labeling requirements of 21 CFR 310.515 for estrogen drug products and 21 CFR 201.56, 201.57, and 201.100 for professional labeling of prescription drug products. In the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of May 4, 1990 (55 FR 18761), the agency announced the revocation of guideline texts of professional and patient labeling for estrogen drug products. The agency determined that the time period to finalize and announce revised guidelines prevented the agency from providing the most current medical information to manufacturers and others. Therefore, in place of guidelines, the agency announced that it would provide assistance in meeting labeling requirements in the form of informal labeling guidance texts.  <!-- PJG 0012 frnewline --> Labeling guidance texts are informal documents. They do not bind or otherwise obligate the agency or a person referring to them and are not formal agency opinions. The agency does not require manufacturers printing professional and patient package inserts to follow the labeling guidance texts. Manufacturers and others are free to use an alternative or modified approach, although they are encouraged to consult with the Division of Metabolism and Endocrine Drug Products (address above) before drafting alternative labeling so that any differences can be resolved prior to the submission of a supplemental application, if such an application is required under 21 CFR 314.70.  <!-- PJG 0012 frnewline --> Interested persons may submit written comments concerning the informal labeling guidance texts to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: June 21, 1994.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Michael R. Taylor, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Commissioner for Policy. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;15605 Filed 6&hyph;27&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            